Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose Selection(Step 1), Non-inferiority(Step 2), Phase II/III Clinical Trials to Evaluated the Efficacy and Safety of Hepatitis B Virus-associated Liver Transplant Patients by Intravenously Injecting GC1102

NCT03519113 is registered in ClinicalTrials.gov with Green Cross Corporation as lead sponsor.

NCT NCT03519113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03519113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose Selection(Step 1), Non-inferiority(Step 2), Phase II/III Clinical Trials to Evaluated the Efficacy and Safety of Hepatitis B Virus-associated Liver Transplant Patients by Intravenously Injecting GC1102
Lead sponsor
Green Cross Corporation
Phase
Phase 2/3
Overall status
Unknown status
Start date
March 29, 2018
Completion date
September 30, 2022
Enrollment
186 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b infection